Please login to the form below

Not currently logged in
Email:
Password:

Realm Therapeutics appoints Sandy Zweifach as non-executive director

But Matthew Hammond and Daniel Hegglin retire

Biopharmaceutical company Realm Therapeutics has appointed Sandy Zweifach as a new non-executive director following the retirement of Matthew Hammond and Daniel Hegglin, both of whom served as non-executive directors.

Zweifach joins the biopharma with over 25 years’ experience in the life science industry, with a background in corporate partnering, business development, operations, private and public investing and capital raising.

He is founder, president and chief executive officer of Nuvelution Pharma, a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a research and development risk-sharing approach that deploys capital and human resources.

Prior to this, Zweifach has served in several leadership roles, including CEO of Ascendancy Healthcare, CEO and president of Pathway Diagnostics and president and CFO of Epoch Biosciences.

Alex Martin, chief executive officer, Realm Therapeutics, said: “I am excited to welcome Sandy to the board.

“His background and experience in both the biopharmaceutical industry and investment banking will be helpful as we progress our pipeline and expand our optionality in 2018 and beyond.”

23rd November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics